Unspecified Adult Solid Tumor Clinical Trial
Official title:
A Continuation Clinical Trial of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors
This phase I trial studies the long-term side effects of the continuation of oral ONC201 in treating patients with solid tumors that have spread to other places in the body who have previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. To evaluate the long-term safety and tolerability of ONC201 (oral ONC201) administered
orally in patients with advanced cancers.
SECONDARY OBJECTIVES:
I. To characterize pharmacokinetics of ONC201. II. To assess serum biomarkers of therapeutic
response to ONC201. III. To assess preliminary antitumor activity of ONC201 as a single agent
in advanced solid tumors.
OUTLINE:
Patients receive oral ONC201 orally (PO) on day 1. Courses repeat every 21 days in the
absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 4 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01450384 -
Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00477607 -
Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin
|
Phase 2/Phase 3 | |
Completed |
NCT02049593 -
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT00938457 -
Stereotactic Radiation Therapy in Treating Patients With Liver Metastases
|
Phase 1/Phase 2 | |
Suspended |
NCT01843413 -
Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases
|
N/A | |
Withdrawn |
NCT03789773 -
Holographic Mm-Wave Imaging in Patients Undergoing Radiation Therapy
|
N/A | |
Completed |
NCT00390156 -
Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00037804 -
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
|
Phase 1 |